Evidence map›Paper›PMID 32817665›Full record

ArticlePloS one2020

Antimalarial drug resistance molecular makers of Plasmodium falciparum isolates from Sudan during 2015-2017.

Maazza Hussien, Muzamil Mahdi Abdel Hamid, Elamin Abdelkarim Elamin, Abdalla O Hassan, Arwa H Elaagip, Abusofyan Hamattallah A Salama, Mohammed H Abdelraheem, Abdelrahim O Mohamed

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. A review on molecular markers ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025
    Review
  6. Article
  7. Bibliometric analysis of antimalarial drug resistance.Frontiers in cellular and infection microbiology · 2024
    Review
  8. Putative molecular markers ofFrontiers in epidemiology · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Pathogens (Basel, Switzerland) · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Maazza HussienDepartment of Medical Parasitology and Entomology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.
Muzamil Mahdi Abdel HamidInstitute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.ORCID 0000-0002-6157-4388
Elamin Abdelkarim ElaminDepartment of Medical Parasitology and Entomology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.
Abdalla O HassanInstitute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
Arwa H ElaagipInstitute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
Abusofyan Hamattallah A SalamaFaculty of Medical Laboratory Sciences, North Kordofan University, Alobied, Sudan.
Mohammed H AbdelraheemInstitute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
Abdelrahim O MohamedDepartment of Biochemistry, Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
University of Khartoum · SDAl-Neelain University · SDUniversity of Kordofan · SD

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundCurrent malaria control and elimination strategies rely mainly on efficacious antimalarial drugs. However, drug resistance is a major threat facing malaria control programs. Determination of drug resistance molecular markers is useful in the monitoring and surveillance of malaria drug efficacy. This study aimed to determine the mutations and haplotypes frequencies of different genes linked with antimalarial drug resistance in certain areas in Sudan.

methodsA total of 226 dried blood spots (DBS) of microscopically diagnosed P. falciparum isolates were collected from Khartoum and three other areas in Sudan during 2015-2017. Plasmodium falciparum confirmation and multiplicity of infection was assessed using the Sanger's 101 SNPs-barcode and speciation was confirmed using regions of the parasite mitochondria. Molecular genotyping of drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, exonuclease, Pfk13, parasite genetic background (PGB) (Pfarps10, ferredoxin, Pfcrt, Pfmdr2)) was also performed. All genotypes were generated by selective regions amplicon sequencing of the parasite genome using the Illumina MiSeq platform at the Wellcome Sanger Institute, UK then genotypes were translated into drug resistance haplotypes and species determination.

findingsIn total 225 samples were confirmed to be P. falciparum. A higher proportion of multiplicity of infection was observed in Gezira (P<0.001) based on the Sanger 101 SNPs -barcode. The overall frequency of mutant haplotype Pfcrt 72-76 CVIET was 71.8%. For Pfmdr1, N86Y was detected in 53.6%, Y184F was observed in 88.1% and D1246Y was detected in 1.5% of the samples. The most frequently observed haplotype was YFD 47.4%. For Pfdhfr (codons 51, 59,108,164), the ICNI haplotype was the most frequent (80.7%) while for Pfdhps (codons 436, 437, 540, 581, 613) the (SGEAA) was most frequent haplotype (41%). The Quadruple mutation (dhfr N51I, S108N + dhps A437G, K540E) was the highest frequent combined mutation (33.9%). In Pfkelch13 gene, 18 non-synonymous mutations were detected, 7 of them were detected in other African countries. The most frequent Pfk13 mutation was E433D detected in four samples. All of the Pfk13 mutant alleles have not been reported to belong to mutations associated with delayed parasite clearance in Southeast Asia. PGB mutations were detected only in Pfcrt N326S\I (46.3%) and Pfcrt I356T (8.2%). The exonuclease mutation was not detected. There was no significant variation in mutant haplotypes between study areas.

conclusionsThere was high frequency of mutations in Pfcrt, Pfdhfr and Pfdhps in this study. These mutations are associated with chloroquine and sulfadoxine-pyrimethamine (SP) resistance. Many SNPs in Pfk13 not linked with delayed parasite clearance were observed. The exonuclease E415G mutation which is linked with piperaquine resistance was not reported.

Indexed as

MutationAdolescentAntimalarialsChildChloroquineDrug ResistanceFemaleHumansMalariaMaleMembrane Transport ProteinsPlasmodium falciparumProtozoan ProteinsPyrimethamineSudanSulfadoxineAntimalarialsChloroquineDHFR protein, Plasmodium falciparumMembrane Transport ProteinsPfCRT protein, Plasmodium falciparumProtozoan ProteinsPyrimethamineSulfadoxineTetrahydrofolate Dehydrogenase

Identifiers

PMID32817665
PMCPMC7446868
OpenAlexW3080370147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.